Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;42(7):737-749.
doi: 10.1007/s40273-024-01377-9. Epub 2024 Apr 27.

Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature

Affiliations
Review

Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature

Gemma E Shields et al. Pharmacoeconomics. 2024 Jul.

Abstract

Cost-effectiveness analyses commonly use population or sample averages, which can mask key differences across subgroups and may lead to suboptimal resource allocation. Despite there being several new methods developed over the last decade, there is no recent summary of what methods are available to researchers. This review sought to identify advances in methods for addressing patient heterogeneity in economic evaluations and to provide an overview of these methods. A literature search was conducted using the Econlit, Embase and MEDLINE databases to identify studies published after 2011 (date of a previous review on this topic). Eligible studies needed to have an explicit methodological focus, related to how patient heterogeneity can be accounted for within a full economic evaluation. Sixteen studies were included in the review. Methodologies were varied and included regression techniques, model design and value of information analysis. Recent publications have applied methodologies more commonly used in other fields, such as machine learning and causal forests. Commonly noted challenges associated with considering patient heterogeneity included data availability (e.g., sample size), statistical issues (e.g., risk of false positives) and practical factors (e.g., computation time). A range of methods are available to address patient heterogeneity in economic evaluation, with relevant methods differing according to research question, scope of the economic evaluation and data availability. Researchers need to be aware of the challenges associated with addressing patient heterogeneity (e.g., data availability) to ensure findings are meaningful and robust. Future research is needed to assess whether and how methods are being applied in practice.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Grutters JPC, Sculpher M, Briggs AH, Severens JL, Candel MJ, Stahl JE, De Ruysscher D, Boer A, Ramaekers BLT, Joore MA. Acknowledging patient heterogeneity in economic evaluation. Pharmacoeconomics. 2013;31:111–23. https://doi.org/10.1007/s40273-012-0015-4 . - DOI - PubMed
    1. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006. - DOI
    1. Ramaekers BLT, Joore MA, Grutters JPC. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health. 2013;16:855–62. https://doi.org/10.1016/J.JVAL.2013.02.013 . - DOI - PubMed
    1. Espinoza MA, Sculpher MJ, Manca A, Basu A. Analysing heterogeneity to support decision making. In: Encyclopedia of Health Economics. Elsevier; 2004. p. 71–6.
    1. Varadhan R, Seeger JD, et al. Estimation and reporting of heterogeneity of treatment effects. In: Velentgas P, Dreyer NA, Nourjah P, et al., editors. Developing a protocol for observational comparative effectiveness research: a user’s guide. Rockville: Agency for Healthcare Research and Quality; 2013.

LinkOut - more resources